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Human biospecimens are subjected to collection, processing, and storage that can significantly alter their
molecular composition and consistency. These biospecimen preanalytical factors, in turn, influence experi-
mental outcomes and the ability to reproduce scientific results. Currently, the extent and type of information
specific to the biospecimen preanalytical conditions reported in scientific publications and regulatory submis-
sions varies widely. To improve the quality of research that uses human tissues, it is crucial that information on
the handling of biospecimens be reported in a thorough, accurate, and standardized manner. The Biospecimen
Reporting for Improved Study Quality (BRISQ) recommendations outlined herein are intended to apply to any
study in which human biospecimens are used. The purpose of reporting these details is to supply others, from
researchers to regulators, with more consistent and standardized information to better evaluate, interpret, com-
pare, and reproduce the experimental results. The BRISQ guidelines are proposed as an important and timely
resource tool to strengthen communication and publications on biospecimen-related research and to help
reassure patient contributors and the advocacy community that their contributions are valued and respected.
Cancer (Cancer Cytopathol) 2011;119:92–101. Published 2011 by the American Cancer Society.*
KEY WORDS: BRISQ, best practices, biobank, biospecimen, human, quality, research, guidelines.
Received: January 21, 2011; Accepted: January 31, 2011
Published online March 22, 2011 in Wiley Online Library (wileyonlinelibrary.com)
DOI: 10.1002/cncy.20147, wileyonlinelibrary.com
Corresponding author: Douglas P. Clark, MD, The Johns Hopkins Hospital, 600 N. Wolfe Street, PATH 406, Baltimore, MD 21287-6940; Fax: (410)
614-9556; dclark@jhmi.edu
1Office of Biorepositories and Biospecimen Research, National Cancer Institute, Bethesda, Maryland; 2Rose Li and Associates, Inc, Bethesda, Maryland;
3Program for Biospecimen Science, Van Andel Research Institute, Grand Rapids, Michigan; 4Biometric Research Branch, Division of Cancer Treatment
and Diagnosis, National Cancer Institute, Bethesda, Maryland; 5Department of Pathology, Johns Hopkins Hospital, Baltimore, Maryland; 6US Military
Cancer Institute, Henry M. Jackson Foundation for the Advancement of Military Medicine, Rockville, Maryland; 7University of Michigan Comprehen-
sive Cancer Center, Ann Arbor, Michigan; 8International Agency for Research on Cancer (IARC), World Health Organization, Lyon, France; 9Paula Kim,
Inc, Translating Research Across Communities (TRAC), Solana Beach, California; 10Center for Devices and Radiological Health, US Food and Drug
Administration, US Department of Health and Human Services, Silver Spring, Maryland; 11Cureline, Inc, South San Francisco, California; 12Erasmus
MC Tissue Bank, Department of Pathology, Rotterdam, Netherlands; 13Office of Rare Diseases Research, National Institutes of Health, Bethesda, Mary-
land; 14H. Lee Moffitt Cancer Center & Research Institute, Tampa, Florida; 15Windber Research Institute, Windber, Pennsylvania; 16Vancouver Island
Center, British Columbia Cancer Agency, Victoria, British Columbia, Canada; 17Life Sciences Division, Lawrence Berkeley National Laboratory, US
Department of Energy, Berkeley, California; 18Division of Cancer Prevention, National Cancer Institute, Bethesda, Maryland
This article is being published simultaneously in Biopreservation and Biobanking by Mary Ann Liebert, Inc. Publishers; Journal of Proteome Research
by American Chemical Society Publications; and Cancer Cytopathology by Wiley-Blackwell, on behalf of the American Cancer Society.
The content of this article does not necessarily reflect the views or policies of the Department of Health and Human Services, nor does mention of
trade names, commercial products, or organizations imply endorsement by the US Government.
*This is a US government work and, as such, is in the public domain in the United States of America.
92 Cancer Cytopathology April 25, 2011
Original Article
Human biospecimens provide the basis for research
that leads to better understanding of human disease
biology and discovery of new treatments tailored to
individual patients with cancer or other diseases. These
biological materials are subjected to several different
collection, processing, and storage factors that can signif-
icantly alter their molecular composition and consis-
tency. These preanalytical factors, in turn, influence
experimental outcomes and the ability to reproduce
scientific results.1-6 Currently, the extent and type of in-
formation specific to the biospecimen preanalytical con-
ditions reported in scientific publications and regulatory
submissions varies widely. To improve the quality of
research that uses human tissues, it is crucial that infor-
mation on the handling of biospecimens be reported in a
thorough, accurate, and standardized manner.
The purpose of this article is to make recommenda-
tions for the reporting of data elements for human biospe-
cimens, defined as solid tissues and bodily fluids, used in
biomedical studies. Cell lines and biospecimen derivatives
such as nucleic acids or proteins, although crucial for bio-
medical research, are not intended to fall within the scope
of these recommendations. The Biospecimen Reporting
for Improved Study Quality (BRISQ) recommendations
are intended to apply to any study in which human bio-
specimens are used. These include biomedical applica-
tions such as translational science, biomarker discovery,
clinical trials, technology development, and diagnostic-
assay and therapeutics development. The recommended
data elements would be reported by an author in a journal
publication, by a company in a regulatory submission,
or by a biorepository distributing biospecimens. It is
intended that the list and the elements within it will be
interpreted, modified, and applied according to the con-
text of the study being reported. It is also recognized that
information corresponding to all data elements may not
be available, but at least for some categories (described
below), the known or unknown status of these elements
should be documented.
The list of data elements discussed includes general in-
formation for consistent documentation of classes of biospe-
cimens and factors that could influence the integrity,
quality, and/or molecular composition of biospecimens.
Reporting the details enumerated in the BRISQ list does not
guarantee biospecimen quality and should not be seen as a
substitute for empirical quality evaluations. The purpose of
reporting these details is to supply others, from researchers
to regulatory agencies, with more consistent and standar-
dized information to better evaluate, interpret, compare,
and reproduce the experimental results. To maintain consis-
tency with federal regulations on research involving human
subjects, information that could enable individual identifica-
tion of research participants should be withheld.
The BRISQ list has been constructed as an initial step
toward defining reporting recommendations. The list will
likely evolve as more is learned about the factors that influ-
ence biospecimen quality and composition, and in turn
their effects on biospecimen analysis. It is envisioned that
future iterations of the BRISQ recommendations might
include changes to the list of elements and the relative
weight thereof in accordance with evidence-based scientific
andmedical findings and technological developments.
MATERIALS AND METHODS
A half-day workshop, Development of Biospecimen
Reporting Criteria for Publications, was held at the
National Cancer Institute (NCI) 2009 Biospecimen
Research Network Symposium (http://biospecimens.can-
cer.gov/meeting/brnsymposium) to initiate a discussion
on biospecimen reporting recommendations. Workshop
attendees included individuals with a broad range of
expertise: laboratory scientists, clinicians, pathologists,
statisticians, patient advocates, biobankers, journal edi-
tors, leaders of relevant professional societies, and other
stakeholders. The attendees noted that reporting guide-
lines covering many aspects of biomedical studies already
exist, particularly guidelines relevant to experimental
design and data reporting. (The EQUATOR project
[http://www.equator-network.org/] provides an extensive
listing of guidelines for health research).
It was proposed that the BRISQ recommendations
apply to all studies that use human biospecimens and,
thus, complement existing guidelines by filling a niche
concerning reporting of biospecimen characteristics and
preanalytical variables.
The attendees further proposed that the BRISQ rec-
ommendations should broadly encompass solid tissues
and bodily fluids, rather than including separate lists for
these biospecimen types. It was also agreed that a commit-
tee to develop biospecimen reporting recommendations
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should be formed to take the effort forward. Many of the
individuals and disciplines participating in the workshop
were included when the BRISQ committee was subse-
quently formed.
Formulation of the recommendations was based on
consideration of what biospecimen information could
enable a science reviewer to fully evaluate or replicate a
reported study. The preliminary list included the most
commonly available data elements. The committee con-
sidered the characteristics of the biospecimens themselves
as well as numerous preanalytical factors. Types of data
elements include the tissue type and the pathology of the
sample; patient characteristics that may influence the
biospecimens, such as vital and disease states; and the col-
lection and handling of the biospecimens, eg, their stabili-
zation, shipping, and storage conditions.
The preliminary list of recommendations was
refined by consulting the NCI Biospecimen Research
Database (http://brd.nci.nih.gov), an online resource
compiling peer-reviewed articles that address biospecimen
science. The Biospecimen Research Database’s terminol-
ogy that was deemed relevant to curating scientific litera-
ture was incorporated into the initial BRISQ list. This
terminology served as a starting point for discussion at
monthly teleconferences by the BRISQ committee.
RESULTS
The committee composed a list of data elements that rep-
resent factors believed to often influence biospecimen
quality and, thus, should be considered for reporting, if
known or applicable, for the particular study; for example,
some list elements will be more applicable to biospeci-
mens collected for a disease-specific study than those col-
lected for a population-based biospecimen resource. For
clarity, these elements are organized according to the life-
cycle of the biospecimen (Fig. 1), which spans the period
immediately before its removal from the patient through
its use in a scientific analysis.
Many reporting elements were discussed, but only
some were approved by consensus for inclusion in the
guidelines. The committee was mindful that certain infor-
mation, although important to report, might not have
direct relevance to the biology or condition of the biospe-
cimen and, therefore, would not be under the purview of
the BRISQ recommendations. The committee attempted
to carefully balance scientific interest in having access to
extensive data about biospecimen collection, processing, and
storage against practical challenges in obtaining such detailed
information. Each reporting element included in the guide-
lines is backed by evidence that the factor could have an
effect on the structural integrity andmolecular characteristics
of the biospecimen or on the ability to perform certain assays
on the biospecimen and obtain reliable results. Whereas the
committee recognized that collection of data on biospeci-
mens can increase the operational costs to collect and use
biospecimens, cost was not factored into the exclusion of
data elements that were or should be considered necessary.
The elements in the BRISQ list are prioritized into 3
tiers according to the relative importance of their being
reported. The first tier, ‘‘Items recommended to report,’’
includes information such as the organ(s) or the anatomi-
cal site from which the biospecimens were derived and the
manner in which the biospecimens were collected, stabi-
lized, and preserved. For quick reference, these items are
summarized in Table 1. Reporting these items need not
be onerous. For example, Beatty et al7 included most
BRISQ Tier 1 items in the following excerpts:
FNA [fine-needle aspiration] specimens were obtained from 55 sur-
gically removed specimens of breast cancer within 1 hour of resec-
tion, before tissue fixation. The aspirates were obtained using a 22-
FIGURE 1. The lifecycle of the biospecimen is illustrated. The preanalytical phase of the lifecycle of the biospecimen includes
each stage from patient to distribution. Preanalytical variables are addressed in the BRISQ list.
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to 25-gauge needle and spread directly on slides and fixed in ethanol
or formalin or placed in CytoLyt for preparation of ThinPrep slides
according to the manufacturer’s protocol. Corresponding FFPE
[formalin-fixed, paraffin-embedded] tissue specimens were fixed in
10% neutral buffered formalin for 18 to 24 hours according to rou-
tine procedures and embedded in paraffin.
All FNA cytologic slides were air dried and stored at room
temperature before FISH analysis.
‘‘Items beneficial to report’’ form the second tier.
These are data elements an evaluator may find helpful to
know but may be slightly less crucial to the scientific con-
tribution or less likely to be annotated, such as the time
from biospecimen excision/acquisition to stabilization.
‘‘Additional items to report’’ compose the third tier. These
include information about conditions that may be useful
to know concerning the biospecimens but are not known
to be as likely to influence research results or are unlikely
to be available to researchers, such as environmental fac-
tors to which patients were exposed or the type of storage
container in which the biospecimens were kept.
The full BRISQ list featured in Table 2 includes each
item and its definition along with additional columns that
were designed for an author or reviewer to track where the
listed items are reported for a particular study. To the right
of the ‘‘Item Descriptions’’ is a column assigning each item
a unique Roman-numeral/letter/number identification
code. The far right column provides space to note where
each item may be found in a manuscript or application.
The far left ‘‘Apply-to’’ column indicates whether the
BRISQ item is applicable to All biospecimen types or is
Table 1. Quick-Reference BRISQ Summary/Checklist: Tier 1 Items to Report If Known and Applicable
Data Elements Examples
Biospecimen type Serum, Urine
Solid tissue, whole blood, or another product derived from a human being
Anatomical site Liver, Antecubital area of the arm
Organ of origin or site of blood draw
Disease status of patients Diabetic, Healthy control
Controls or individuals with the disease of interest
Clinical characteristics of patients Pre-menopausal breast cancer patients
Available medical information known or believed to be pertinent to the
condition of the biospecimens
Vital State of patients Postmortem
Alive or deceased patient when biospecimens were obtained
Clinical diagnosis of patients Breast cancer
Patient clinical diagnoses (determined by medical history, physical
examination, and analyses of the biospecimen) pertinent to the study
Pathology diagnosis Her2-negative intraductal carcinoma
Patient pathology diagnoses (determined by macro and/or microscopic
evaluation of the biospecimen at the time of diagnosis and/or prior
to research use) pertinent to the study
Collection mechanism Fine needle aspiration, Pre-operative blood draw
How the biospecimens were obtained
Type of stabilization Heparin, On ice
The initial process by which biospecimens were stabilized during
collection
Type of long-term preservation Formalin fixation, freezing
The process by which the biospecimens were sustained after collection
Constitution of preservative 10% neutral-buffered formalin, 10 USP Heparin Units/mL
The make-up of any formulation used to maintain the biospecimens in a
non-reactive state
Storage temperature 80 C, 20 to 25 C
The temperature or range thereof at which the biospecimens were kept
until distribution/analysis.
Storage duration 8 days, 5 to 7 years
The time or range thereof between biospecimen acquisition and distribution or analysis.
Shipping temperature 170 C to 190 C
The temperature or range thereof at which biospecimens were kept during shipment
or relocation.
Composition assessment & selection Minimum 80% tumour nuclei & maximum 50% necrosis
Parameters used to choose biospecimens for the study
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Table 2. BRISQ Information to Consider Reporting in Publications That Employ Human Biospecimens
Biospecimen Reporting for Improved Study Quality (BRISQ): Items to Consider Reporting
if Known and Applicable
Apply to Tier # Item Description Item # Location
I. Pre-acquisition
All Tier 1 Biospecimen type. Solid tissue, whole blood, serum/plasma,
isolated cells, urine, secretions, or another product derived
from a human being.
I.a. _________________
All Tier 1 Anatomical or collection site. In standard terminology,
organ(s) of origin or site of blood draw.
I.a.1. _________________
All Tier 1 Biospecimen disease status. From controls or individuals with the
disease of interest; in the case of solid tissue, whether it is from
disease site or normal adjacent (not involved but from the same
anatomical site as a disease specimen in the same patient).
I.a.2. _________________
All Tier 1 Clinical characteristics of patients. In standard terminology, available
medical information known or believed to be pertinent to the
condition of the biospecimens.
I.b. _________________
All Tier 1 Vital state. Alive or deceased when biospecimens were obtained I.b.1 _________________
All Tier 3 Disease state. Patient condition relative to disease and treatment, if
known (eg, during- or post-therapy; acute, chronic, or terminal stage).
I.b.1.1. _________________
All Tier 3 Cause of death. For postmortem biospecimens, the cause of death
and other diseases present at the time of death.
I.b.1.2. _________________
All Tier 3 Agonal state. The patients’ physical condition immediately preceding
death (eg, prolonged degeneration or relatively healthy)
I.b.1.3. _________________
All Tier 1 Diagnosis. Patient diagnoses pertinent to the study being
conducted, using an accepted system of standards (eg, the
Systemized Nomenclature of Medicine or the International
Classification of Diseases). Please note that clinical and
pathology diagnoses are not always the same.
I.b.2. _________________
All Tier 1 Clinical. Patient clinical diagnoses (determined by medical
history, physical examination, and analyses of a biospecimen)
pertinent to the study being conducted.
I.b.2.1. _________________
All Tier 1 Pathology. Patient pathology diagnoses (determined by macro
and/or microscopic evaluation of a biospecimen at the time of
diagnosis and/or prior to research use) pertinent to the
study being conducted.
I.b.2.2. _________________
All Tier 2 Time between diagnosis and sampling. The time or range of time
between disease diagnosis and sample acquisition.
1.b.2.3 _________________
All Tier 3 Exposures. Neoadjuvant therapy, other current or past medical
treatments or environmental factors that might influence the condition
of the biospecimen (eg, chemo-and radiation therapy,
blood thinner, smoking status).
I.b.3. _________________
All Tier 3 Reproductive status. The hormonal or reproductive state of the
patients (eg, pregnant, pre-pubescent, post-menopausal).
I.b.4. _________________
All Tier 2 Patient demographic information. Demographic information that might be
relevant to the condition of the biospecimens (eg, age range, gender).
I.c. _________________
All Tier 2 Accrual scheme. Whether the biospecimens were obtained for the study
being conducted or for a generalized collection such as a
population-based biospecimen resource (i.e. retrospective or prospective
procurement); whether any standard operating procedures (SOPs) were
employed and whether these SOPs are available to others upon request.
Reference any clinical trials relevant to the accrual scheme.
I.d. _________________
All Tier 2 Nature of the biobanking institution(s). The biobanking context in which
the biospecimens were obtained (eg, as part of an internal collection
or a biospecimen-acquisition network); include name, location, and
primary contact details such as email address or Web site and
reference to any pertinent SOPs.
I.e. _________________
II. Acquisition
All Tier 1 Collection mechanism and parameters. How the biospecimens were
obtained (eg, fine needle aspiration, pre-operative blood draw).
II.a. _________________
Tissue Tier 3 Time from cessation of blood flow in vivo to biospecimen
excision/acquisition. The time or range of times that the
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Table 2. (Continued)
Biospecimen Reporting for Improved Study Quality (BRISQ): Items to Consider Reporting
if Known and Applicable
Apply to Tier # Item Description Item # Location
All Tier 2 Time from biospecimen excision/acquisition to stabilization. The time or
time-range between when the biospecimens were obtained (eg, blood
drawn or tumor surgically removed) and when they were stabilized.
For postmortem biospecimens, list the postmortem interval range
(i.e. the time from death to stabilization of the biospecimen).
II.c. _________________
All Tier 2 Temperature between biospecimen excision/acquisition and stabilization.
The temperature or range thereof at which biospecimens were kept between
when biospecimens were obtained (eg, blood drawn or tumor surgically
removed) and when they were stabilized. For postmortem biospecimens, the
temperature at which the cadaver was stored during the postmortem interval.
II.d. _________________
Fluid Tier 2 Collection container. The kind of tube into which biospecimens were
captured as they left the body.
II.e. _________________
III. Stabilization/Preservation
All Tier 1 Mechanism of stabilization. The initial process by which biospecimens
were stabilized during collection [eg, snap or controlled-rate
freezing, fixation, additive (heparin, citrate, or EDTA), none].
III.a. _________________
All Tier 1 Type of long-term preservation. The process by which the
biospecimens were sustained after collection (eg, freezing and
at which temperature; formalin fixation, paraffin embedding;
additive; none). Please note, this might or might not differ
from the mechanism of stabilization.
III.b. _________________
All Tier 1 Constitution and concentration of fixative/preservation solution.
The make-up of any formulation employed to maintain the
biospecimens in a non-reactive state (eg, 10
percent neutral-buffered formalin or 10 USP Heparin Units/mL).
III.b.1. _________________
Tissue Tier 2 Time in fixative/preservation solution. The time or range thereof that
biospecimens were exposed to the preservation medium.
III.b.2. _________________
Tissue Tier 2 Temperature during time in preservation solution. The temperature of
the medium during the preservation process.
III.b.3. _________________
Fluid Tier 2 Aliquot volume. The amount in each liquid biospecimen sample. III.c. _________________
Tissue Tier 2 Specimen size. The approximate size or weight of solid biospecimen
samples processed (eg, cubes approximately 0.5 cm on a side, 0.5 gram).
III.d. _________________
IV. Storage/Transport
Storage parameters. The conditions under which the biospecimens
were maintained until analysis.
All Tier 1 Storage temperature. The temperature or range thereof at which
the biospecimens were maintained until distribution or analysis.
IV.a.1. _________________
All Tier 1 Storage duration. The time or range thereof between biospecimen
acquisition and distribution or analysis.
IV.a.2. _________________
All Tier 2 Storage details. Other conditions under which specimens were
maintained during storage (eg, to minimize oxidation).
IV.a.3. _________________
All Tier 3 Type of storage container. The vessel in which biospecimens were kept. IV.a.4. _________________
All Tier 3 Type of slide. The microscope slides to which biospecimens were affixed. IV.a.5. _________________
Shipping parameters. The conditions to which biospecimens were
exposed during each shipment or inventory management.
All Tier 1 Shipping temperature(s). The temperature or range thereof at which
biospecimens were maintained during each shipment or relocation.
IV.b.1. _________________
All Tier 2 Shipping duration. The time, estimate, or range thereof that the
biospecimens spent in shipment each time they were transported.
IV.b.2. _________________
All Tier 3 Type of transport container. The type of vessel (eg, pre-manufactured
shipping container, polystyrene box) and the packing material in which
the biospecimens were transported.
IV.b.3. _________________
All Tier 3 Shipping parameters. Other conditions under which the biospecimens
were transported (eg, vacuum sealing, desiccant, packing material).
Please note any deviations from standard operating procedures that
might influence the condition of the biospecimens (eg, shipping
anomalies that exposed paraffin blocks to high temperatures).
IV.b.4. _________________
Freeze-thaw parameters. The conditions to which biospecimens were
subjected during any thaw events.
(Continued)
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more appropriate for solid Tissue biospecimens or Fluid
biospecimens (such as blood, urine, or other fluids). For
example, item III.b, ‘‘Type of long-term preservation,’’ is
pertinent to all types of biospecimens; item III.b.2, ‘‘Time
in fixative/preservative solution,’’ is more relevant to solid
tissue than to fluid biospecimens; and item III.c, ‘‘Aliquot
volume,’’ applies more often to fluid than to solid tissue
biospecimens.
When reporting elements of the BRISQ list, stand-
ard operating procedures specifying many of the pertinent
details, such as blood-collection protocols, may be pro-
vided or referenced; any referenced documents should be
publicly available. It is preferable that most Tier 1 items
relevant to the biospecimen and particular scientific study
be reported directly in the intended publication rather
than be cited from another document. Detailed descrip-
tions that are too lengthy to be accommodated should be
made available as supplementary materials online.
Whether the laboratory performing the study was operat-
ing under any formal certification or accreditation should
be stated when applicable to the study being reported.
The BRISQ committee discussed whether to request
information on whether the biorepository and/or
researcher had obtained ethical clearance to collect the bio-
specimens and perform the study. Clearance from an insti-
tutional review board or similar body is important to report
Table 2. (Continued)
Biospecimen Reporting for Improved Study Quality (BRISQ): Items to Consider Reporting
if Known and Applicable
Apply to Tier # Item Description Item # Location
Fluid Tier 2 Number of freeze-thaw cycles. The number, estimate, or range thereof
of thaw-refreeze events to which biospecimens were subjected
prior to analysis.
IV.c.1. _________________
Fluid Tier 3 Duration of thaw events. The amount of time or range thereof the
biospecimens spent thawed prior to the final thaw before processing.
IV.c.2. _________________
Fluid Tier 3 Time from last thaw to processing. The time or range of times
between unfreezing and analysis.
IV.c.3. _________________
All Tier 3 Temperature between last thaw and processing. The temperature
at which biospecimens were kept between unfreezing and analysis.
IV.c.4. _________________
V. Quality Assurance Measures Relevant to the Extracted Product and Processing Prior to Analyte Extraction and
Evaluation
All Tier 1 Composition assessment and selection. Any parameters that were
used to evaluate and/or choose biospecimens for inclusion
in the study.
V.a. _________________
All Tier 2 Gross and microscopic review. The anatomical characteristics of
the biospecimens in the study and the relevant qualifications of the
individual performing the review (eg, anatomist, pathologist,
hematologist, microbiologist, or researcher).
V.a.1. _________________
Tissue Tier 2 Proximity to primary pathology of interest. Whether the biospecimen
was taken from a region adjacent to or distal from another region
of interest, such as a tumor or area of necrosis. Give approximate
distances if known.
V.a.2. _________________
All Tier 2 Method of enrichment for relevant component(s). The method by
which pertinent portions of the biospecimen were separated from the
rest of the biospecimen (eg, laser-capture microdissection of tissue,
block selection for region of lesion, centrifugation of blood).
V.a.3. _________________
All Tier 2 Details of enrichment for relevant component(s). The parameters used
to separate pertinent portions of the biospecimen from the rest of the
biospecimen, if applicable (eg, centrifugation speed and temperature).
V.a.4. _________________
Tissue Tier 3 Embedding reagent/medium. Any formulation used to enclose the
biospecimens (eg, paraffin).
V.b. _________________
All Tier 2 Quality assurance measures. Any methods used to assess the quality
of the biospecimens relevant to the biomolecular analyte, when these
methods were employed (eg, prior to long-term storage or
immediately before experimental analysis), and the results
(eg, RNA integrity number, hemolysis assessment).
V.c. _________________
Bold: Tier 1–Recommended to report.
Plain: Tier 2–Beneficial to report.
Italics: Tier 3–Additional items to report.
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in publications, and its reporting is generally required by
journals. However, it is not immediately pertinent to the
structural integrity and molecular characteristics of the
biospecimen and, thus, is not included in the BRISQ rec-
ommendations. Similarly, accurate biospecimen-tracking
mechanisms are essential to biobanking but are not imme-
diately pertinent to the condition of the biospecimen and,
thus, are also not included in the BRISQ data-elements list.
Surgical parameters, such as type of anesthesia, or
receipt of blood, or other intraoperative infusates, were
recognized to be of potential significance to the condition
of the biospecimens. However, these data often are not
known. When it is available, information on anesthesia
and intraoperative treatments that may influence the con-
dition of the biospecimens should be reported. These ele-
ments were not included in the BRISQ list because,
currently, such information is rarely available or not
required to be recorded as part of biospecimen collection.
If or when surgical parameters are determined to be criti-
cal through systematic biospecimen research studies, these
elements will be integrated into future recommendations.
Several preservation parameters known to influence
the condition of biospecimens and the results of analyses
have been included in the list of recommendations.
Researchers should state the rationale for the chosen pres-
ervation parameters. For example, if the type and temper-
ature of the biospecimen preservative were selected to
optimize stability, extraction, and analysis of a particular
analyte, then this should be mentioned.
The BRISQ committee recognized the need for
greater specificity in the reported anatomic and histologic
details concerning solid tissue biospecimens. The commit-
tee agreed that the level of detail with which pathology
characteristics are reported should be enough to sufficiently
address the scientific research question. These characteris-
tics include not only the tissue site of the biospecimen and
the relation of the biospecimen to the pertinent clinical di-
agnosis within the tissue site but also the composition and
pathology within the biospecimen where relevant.
The BRISQ committee included members of the
National Cancer Institute (NCI) Office of Biorepositories
and Biospecimen research (OBBR), participants from the
OBBR Biospecimen Research Network Symposium, and
members of the International Society for Biological and Envi-
ronmental Repositories (ISBER), as well as the committees
responsible for the REporting recommendations for tumor
MARKer prognostic studies (REMARK),8 and STrengthen-
ing the Reporting of OBservational studies in Epidemiology
(STROBE)9 guidelines. Essential harmonization with similar
efforts underway by these groups is ongoing.
DISCUSSION
An adage in the business community states, ‘‘That which
is measured improves. That which is measured and
reported improves exponentially.’’ The BRISQ reporting
recommendations represent the product of extensive dis-
cussion and input from researchers with varied types of ex-
pertise and frommany stakeholders, all of whom share the
common goal of improving biospecimen reporting and,
by extension, fields in which biospecimens are used. The
committee believes that by providing details concerning
preanalytical factors that could affect assay results, investi-
gators will further improve the quality of biomedical stud-
ies, including research for developing cancer biomarkers
for screening, early detection, and treatment.
Adoption of the BRISQ recommendations is
expected to help authors, reviewers, editors, and regula-
tory officials evaluate whether sufficient information on
the biospecimens has been provided to enable assessment
of the influence of preanalytical biospecimen factors on
study results. If reported, this information will allow
improved evaluation, interpretation, comparison, and
reproduction of the results from studies that use human
biospecimens. Although items in any Tier may not be
available or in Tiers 2 or 3 may not be considered signifi-
cant to report, increased awareness of their potential influ-
ence on biospecimen studies may lead to improved
tracking and reporting in the future.
The BRISQ recommendations may be implemented
by anyone who reports on studies involving biospecimens.
Reviewers, editors, and regulatory officials could also use
the list as a tool for evaluating whether sufficient biospeci-
men information has been included in a manuscript or
application. In addition, the recommendations could be
used by investigators requesting biospecimens from a bio-
specimen resource: essential items on the list may be
checked off to indicate that they are required annotations
for the desired samples. Elements of BRISQ that docu-
ment preanalytical variables for tissue biospecimens could
be economically captured by using a reporting system
such as the Standard PREanalytical Code, or SPREC,
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which was recently published by the ISBER Working
Group on Biospecimen Science.10
BRISQ reporting items will not necessarily be ap-
plicable to every study, and authors and reviewers are
urged to use their judgment to decide which factors are
essential. It is not always possible for investigators to ascer-
tain every recommended element for every biospecimen,
even for Tier 1 items, but unknown elements relevant to
the study being reported should be fully acknowledged
with a discussion of possible implications that the missing
information might have on the study conclusions.
Unknown or unreported Tier 1 data elements should not
be considered a reason for automatic dismissal of a report
or conditional for the award of a grant. The final decision
on acceptability of missing Tier 1 information should be
specific to the study context.
When consulting the BRISQ list, researchers
should evaluate the importance of each item in the con-
text of the study and adjust their reporting accordingly.
An item such as ‘‘method of enrichment for relevant com-
ponents,’’ listed here as Tier 2 could, for example, in the
context of a study comparing the efficacy of various
enrichment methods, be essential to report and, thus,
should be considered Tier 1 for that study. The converse
may also be true when, for example, an item listed here as
Tier 2, such as ‘‘temperature between acquisition and sta-
bilization,’’ is less pertinent to the study at hand—perhaps
because the time at this temperature was negligible—and
should be considered Tier 3.
It is hoped that consideration of the BRISQ recom-
mendations will sensitize the biobanking and research
communities and their funding agencies to the impor-
tance of tracking preanalytical variables, leading to more
judicious selection and handling of experimental human
specimens and thus improved study quality. Anecdotally,
recommendations such as REMARK seem to have had
the effect of spurring researchers to consider the recom-
mendations in advance of conducting their investiga-
tions, with the result that researchers may take greater
care in the design, conduct, and analysis of their studies.
The BRISQ committee envisions a similar trajectory for
preanalytical biospecimen data elements. Thus, not only
might overall quality of publications improve, but the
quality of human-biospecimen-dependent investigation
in general might improve over time with the formation
and adoption of publication recommendations. It is
anticipated that biospecimen resources might use these
recommendations to improve on their existing standard
operating procedures and annotation thereof. Such
improvements could include the acquisition of addi-
tional relevant biospecimen data based on the BRISQ
recommendations and the release of all such data to
researchers as a standard procedure. In this way, biospeci-
men resources could become major players in the univer-
sal application of these recommendations.
Patient contribution of biospecimens for research is
a voluntary, generous action aimed at advancing scientific
discovery and progress. The research team, pathologist,
and biorepository systems, as the stewards of these biospe-
cimens, have a responsibility to be vigilant and persistent
in using methods and practices that protect and preserve
the highest possible quality biospecimen and its associated
data. The BRISQ guidelines are proposed as an important
and timely resource to strengthen communication and
publications around biospecimen-related research and to
reassure patient contributors and the advocacy community
that the contributions are valued and respected. Researchers
are further encouraged to strengthen public outreach and
education around the use and potential of human biospeci-
mens11 and the biorepository community as these are
emerging and potentially misunderstood areas.
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